Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 4/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30239755 | 1.00 | BDKRB1 (0.36) | BDKRB1USP30GAAAAK1BACE1 | |
| SCHEMBL1878236 | 0.81 | GAA (0.36) | USP30GAAAAK1PRMT5WDR77 | |
| SCHEMBL29771969 | 0.81 | GAA (0.36) | USP30GAAAAK1PRMT5WDR77 | |
| SCHEMBL1875351 | 0.81 | GAA (0.36) | USP30GAAAAK1PRMT5WDR77 | |
| SCHEMBL1875354 | 0.81 | GAA (0.36) | USP30GAAAAK1PRMT5WDR77 | |
| SCHEMBL20185068 | 0.78 | GAA (0.38) | BDKRB1USP30GAAAAK1SCN9A | |
| SCHEMBL30239880 | 0.78 | GAA (0.38) | BDKRB1USP30GAAAAK1SCN9A | |
| SCHEMBL23336924 | 0.77 | USP30 (0.34) | BDKRB1USP30GAAAAK1BACE1 | |
| SCHEMBL26052378 | 0.77 | USP30 (0.34) | BDKRB1USP30GAAAAK1BACE1 | |
| SCHEMBL20204455 | 0.77 | FFAR1 (0.30) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3573965-B1 | INDANYLAMINOPYRAZINYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2021-06-23 | — | — | EP | disclosed |
| EP-3544958-B1 | INDANYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2021-03-24 | — | — | EP | disclosed |
| EP-3544958-A1 | INDANYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2019-10-02 | — | — | EP | disclosed |
| US-10253004-B2 | Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-04-09 | — | — | US | disclosed |
| US-10253004-B2 | Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-04-09 | — | — | US | disclosed |
| US-10125101-B2 | Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-11-13 | — | — | US | disclosed |
| WO-2018138026-A1 | INDANYLAMINOPYRAZINYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018138026-A1 | INDANYLAMINOPYRAZINYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-08-02 | — | — | WO | disclosed |
| US-20180208560-A1 | Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-07-26 | — | — | US | disclosed |
| US-20180208560-A1 | Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-07-26 | — | — | US | disclosed |
| US-20180208560-A1 | Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-07-26 | — | — | US | disclosed |
| US-20180148411-A1 | INDANYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-05-31 | — | — | US | disclosed |
| US-20180148411-A1 | INDANYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-05-31 | — | — | US | disclosed |
| US-20180148411-A1 | INDANYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-05-31 | — | — | US | disclosed |
| WO-2018095877-A1 | INDANYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018095877-A1 | INDANYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253004-B2 | Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | GPR119, GPR55, GPR65 | BDKRB1 64/4885USP30 2440/4885GAA 4429/4885 |
| US-10125101-B2 | Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | GPR119, GPR65, GPR55 | BDKRB1 69/4885USP30 2063/4885GAA 4040/4885 |
| US-20180208560-A1 | Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | GPR119, GPR55, GPR65 | BDKRB1 64/4885USP30 2440/4885GAA 4429/4885 |
| US-20180148411-A1 | INDANYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | GPR119, GPR65, GPR55 | BDKRB1 69/4885USP30 2063/4885GAA 4040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.